Dogwood Therapeutics Inc (DWTX)

$1.70 +0.01 (0.59%)
Market Cap 56.45M
Revenue (ttm) 0.00
Net Income (ttm) -34.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 92,900
Avg Vol 106,730
Day's Range N/A - N/A
Shares Out 33.40M
Stochastic %K 81%
Beta 1.68
Analysts Strong Sell
Price Target $14.00

Company Profile

Dogwood Therapeutics, Inc., a development-stage biotechnology company, focuses on the development of medicine to treat pain and fatigue-related disorders. Its lead product candidates include IMC-1, a combination of famciclovir and celecoxib that has completed Phase 2b clinical trial to treat fibromyalgia; Halneuron, which is in Phase 2b clinical trial for the treatment of chemotherapy-induced neuropathic pain and cancer pain, as well as pre-clinical trial for acute surgical pain; and IMC-2, a co...

Industry: Biotechnology
Sector: Healthcare
Phone: 866 620 8655
Website: dwtx.com
Address:
44 Milton Avenue, Alpharetta, United States
BiotechGoldenEra
BiotechGoldenEra May. 5 at 2:24 AM
$DWTX dod feces
1 · Reply
Drainomight
Drainomight May. 4 at 2:43 PM
$DWTX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 4 at 2:25 PM
$DWTX RSI: 32.19, MACD: -0.2487 Vol: 0.24, MA20: 1.62, MA50: 2.26 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Drainomight
Drainomight Apr. 28 at 12:19 PM
$DWTX better days are coming
0 · Reply
hammerfall43
hammerfall43 Apr. 24 at 3:14 PM
$DWTX Give me 1$ please
0 · Reply
MamawsBiscuits
MamawsBiscuits Apr. 23 at 9:28 PM
$DWTX hmmm
0 · Reply
DanielDiaz23
DanielDiaz23 Apr. 23 at 7:23 PM
$DWTX why does it fall?
1 · Reply
focafoca99
focafoca99 Apr. 23 at 6:12 PM
$DWTX licensed IMC-1 and IMC-2 to PRIDCor in a worldwide partnership that could be worth up to $100 million plus royalties and other future economics.
0 · Reply
Drainomight
Drainomight Apr. 23 at 1:57 PM
$DWTX we should move up a little on the news
1 · Reply
hammerfall43
hammerfall43 Apr. 23 at 1:21 PM
$DWTX
0 · Reply
Latest News on DWTX
Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

May 7, 2026, 8:30 AM EDT - 6 days ago

Dogwood Therapeutics to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Dogwood announces commercialization partnership with PRIDCor

2026-04-23T13:30:03.000Z - 20 days ago

Dogwood announces commercialization partnership with PRIDCor

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Apr 23, 2026, 9:00 AM EDT - 20 days ago

Dogwood Therapeutics Announces Worldwide Development and Commercialization Partnership for Anti-Viral Assets with Potential Value up to $100M

Dogwood announces FDA acceptance of SP16 investigational new drug application

2026-04-15T13:22:56.000Z - 4 weeks ago

Dogwood announces FDA acceptance of SP16 investigational new drug application

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Apr 15, 2026, 9:00 AM EDT - 4 weeks ago

Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy

Dogwood sees cash runway into 4Q26

2026-03-18T12:42:15.000Z - 2 months ago

Dogwood sees cash runway into 4Q26

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 18, 2026, 8:30 AM EDT - 2 months ago

Dogwood Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial

2026-02-02T13:35:35.000Z - 3 months ago

Dogwood announces 50% enrollment in ongoing Halneuron Phase 2b trial

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

Feb 2, 2026, 8:30 AM EST - 3 months ago

Dogwood Therapeutics Announces 50% Enrollment in Ongoing Halneuron® Phase 2b Trial, Top Line Results Anticipated in Q3 2026

Dogwood files to sell 6.43M shares of common stock for holders

2026-01-15T21:25:14.000Z - 4 months ago

Dogwood files to sell 6.43M shares of common stock for holders

Dogwood announces financing of up to $26.8M

2026-01-12T13:55:35.000Z - 4 months ago

Dogwood announces financing of up to $26.8M

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

Jan 12, 2026, 8:30 AM EST - 4 months ago

Dogwood Therapeutics, Inc. Announces Financing of up to $26.8 Million to Progress Halneuron® Through Phase 2b Development

Dogwood announces interim Phase 2b trial results on Halneuron

2025-12-22T15:20:25.000Z - 5 months ago

Dogwood announces interim Phase 2b trial results on Halneuron

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

Dec 22, 2025, 10:15 AM EST - 5 months ago

Dogwood Therapeutics Announces Positive Interim Phase 2b Clinical Trial Results in Chemotherapy Induced Neuropathic Pain

Dogwood files for IP protection for synthetic Halneuron

2025-12-02T13:30:43.000Z - 5 months ago

Dogwood files for IP protection for synthetic Halneuron

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

Dec 2, 2025, 8:00 AM EST - 5 months ago

Dogwood Therapeutics Files New Synthetic Halneuron(R) Intellectual Property Protection Projected to Extend Exclusivity Period Up to 2045

Dogwood Therapeutics Transcript: EGM 2025

Nov 21, 2025, 10:00 AM EST - 6 months ago

Dogwood Therapeutics Transcript: EGM 2025

Dogwood enrolls first 100 patients in Halneuron Phase 2b trial

2025-11-11T13:55:32.000Z - 6 months ago

Dogwood enrolls first 100 patients in Halneuron Phase 2b trial

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

Nov 11, 2025, 8:45 AM EST - 6 months ago

Dogwood Announces Enrollment of First 100 Patients in Ongoing Halneuron(R) Phase 2b Trial, Interim Sample Size Analysis on Track for December 2025

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 8:45 AM EST - 6 months ago

Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Oct 30, 2025, 9:15 AM EDT - 6 months ago

Dogwood Therapeutics to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Oct 14, 2025, 8:45 AM EDT - 7 months ago

Dogwood Therapeutics to Participate at the Maxim Growth Summit 2025

Dogwood to present on Halneuron pain research program

2025-10-07T13:30:11.000Z - 7 months ago

Dogwood to present on Halneuron pain research program

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

Oct 7, 2025, 8:45 AM EDT - 7 months ago

Dogwood Therapeutics, Inc. Chief Medical Officer, Dr. Michael Gendreau, to Present an Overview of the Halneuron® Pain Research Program at the 19th Annual Pain Therapeutics Summit

Dogwood files to sell 28.04M shares of common stock for holders

2025-10-01T20:20:32.000Z - 7 months ago

Dogwood files to sell 28.04M shares of common stock for holders

Dogwood price target raised to $12 from $10 at H.C. Wainwright

2025-09-30T10:15:45.000Z - 8 months ago

Dogwood price target raised to $12 from $10 at H.C. Wainwright

Dogwood Therapeutics Transcript: Study Update

Sep 29, 2025, 8:30 AM EDT - 8 months ago

Dogwood Therapeutics Transcript: Study Update

Dogwood secures royalty free license to develop, commercialize SP16

2025-09-29T11:20:42.000Z - 8 months ago

Dogwood secures royalty free license to develop, commercialize SP16

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Sep 29, 2025, 7:15 AM EDT - 8 months ago

Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

Dogwood Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 5, 2025, 7:00 AM EDT - 8 months ago

Dogwood Therapeutics Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Sep 3, 2025, 9:15 AM EDT - 9 months ago

Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Aug 13, 2025, 9:00 AM EDT - 9 months ago

Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Aug 7, 2025, 1:08 PM EDT - 9 months ago

Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Aug 6, 2025, 9:15 AM EDT - 10 months ago

Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

Dogwood Therapeutics Transcript: Sidoti's Small-Cap Virtual Conference

Jun 11, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics Transcript: Sidoti's Small-Cap Virtual Conference

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Jun 3, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

Dogwood files $150M mixed securities shelf

2025-05-23T21:30:13.000Z - 1 year ago

Dogwood files $150M mixed securities shelf

Dogwood reports Q1 EPS ($8.45) vs. ($1.68) last year

2025-05-08T13:14:16.000Z - 1 year ago

Dogwood reports Q1 EPS ($8.45) vs. ($1.68) last year

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

May 8, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics Announces First Quarter 2025 Financial Results

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

May 1, 2025, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Apr 11, 2025, 9:15 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Receives Nasdaq Confirmation of Compliance

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Apr 3, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Regains Nasdaq Compliance

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Mar 31, 2025, 3:45 PM EDT - 1 year ago

Dogwood Therapeutics Announces Fourth Quarter and Full Year 2024 Financial Results

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Mar 18, 2025, 8:45 AM EDT - 1 year ago

Dogwood Therapeutics Announces Dosing of First Patient in Phase 2b Trial Evaluating Halneuron® in Patients with Chemotherapy-Induced Neuropathic Pain

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Mar 13, 2025, 9:00 AM EDT - 1 year ago

Dogwood Therapeutics, Inc. Announces Pricing of $4.8 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules

Dogwood Therapeutics Earnings Call Transcript: Q3 2024

Nov 7, 2024, 8:30 AM EST - 1 year ago

Dogwood Therapeutics Earnings Call Transcript: Q3 2024

Dogwood Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Oct 17, 2024, 9:30 AM EDT - 1 year ago

Dogwood Therapeutics Transcript: Maxim Group’s 2024 Healthcare Virtual Summit

Dogwood Therapeutics Transcript: M&A Announcement

Oct 7, 2024, 8:30 AM EDT - 1 year ago

Dogwood Therapeutics Transcript: M&A Announcement

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Oct 7, 2024, 7:05 AM EDT - 1 year ago

Virios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: “DWTX”)

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Aug 8, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Second Quarter 2024 Financial Results

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Aug 1, 2024, 9:41 AM EDT - 1 year ago

Virios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

Jul 23, 2024, 9:15 AM EDT - 1 year ago

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 22, 2024, 1:30 PM EDT - 2 years ago

Virios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 19, 2024, 8:53 PM EDT - 2 years ago

Virios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

May 17, 2024, 4:10 PM EDT - 2 years ago

Virios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b Study

Dogwood Therapeutics Earnings Call Transcript: Q1 2024

May 9, 2024, 8:30 AM EDT - 2 years ago

Dogwood Therapeutics Earnings Call Transcript: Q1 2024

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

May 9, 2024, 7:45 AM EDT - 2 years ago

Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

May 2, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Mar 26, 2024, 9:15 AM EDT - 2 years ago

Virios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVID

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Feb 29, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial Results

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Feb 28, 2024, 9:15 AM EST - 2 years ago

Virios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming Milestones

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Jan 22, 2024, 9:00 AM EST - 2 years ago

Virios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVID

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Jan 2, 2024, 7:05 AM EST - 2 years ago

Virios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVID

Dogwood Therapeutics Earnings Call Transcript: Q3 2023

Nov 13, 2023, 8:30 AM EST - 2 years ago

Dogwood Therapeutics Earnings Call Transcript: Q3 2023

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Nov 13, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Nov 6, 2023, 7:05 AM EST - 2 years ago

Virios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Oct 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Sep 18, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Termination of At-The-Market Sales Agreement

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Sep 12, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Aug 14, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Halt to At-The-Market Offering Sales

Dogwood Therapeutics Earnings Call Transcript: Q2 2023

Aug 10, 2023, 8:30 AM EDT - 2 years ago

Dogwood Therapeutics Earnings Call Transcript: Q2 2023

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Aug 10, 2023, 7:05 AM EDT - 2 years ago

Virios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate Update

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Aug 9, 2023, 7:05 AM EDT - 3 years ago

Virios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for Fibromyalgia

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

Jul 17, 2023, 7:05 AM EDT - 3 years ago

Virios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept Study

BiotechGoldenEra
BiotechGoldenEra May. 5 at 2:24 AM
$DWTX dod feces
1 · Reply
Drainomight
Drainomight May. 4 at 2:43 PM
$DWTX
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 4 at 2:25 PM
$DWTX RSI: 32.19, MACD: -0.2487 Vol: 0.24, MA20: 1.62, MA50: 2.26 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Drainomight
Drainomight Apr. 28 at 12:19 PM
$DWTX better days are coming
0 · Reply
hammerfall43
hammerfall43 Apr. 24 at 3:14 PM
$DWTX Give me 1$ please
0 · Reply
MamawsBiscuits
MamawsBiscuits Apr. 23 at 9:28 PM
$DWTX hmmm
0 · Reply
DanielDiaz23
DanielDiaz23 Apr. 23 at 7:23 PM
$DWTX why does it fall?
1 · Reply
focafoca99
focafoca99 Apr. 23 at 6:12 PM
$DWTX licensed IMC-1 and IMC-2 to PRIDCor in a worldwide partnership that could be worth up to $100 million plus royalties and other future economics.
0 · Reply
Drainomight
Drainomight Apr. 23 at 1:57 PM
$DWTX we should move up a little on the news
1 · Reply
hammerfall43
hammerfall43 Apr. 23 at 1:21 PM
$DWTX
0 · Reply
biotrade123
biotrade123 Apr. 22 at 10:35 PM
$DWTX dead board??
0 · Reply
biotrade123
biotrade123 Apr. 22 at 6:07 PM
$DWTX looks like someone dumped 11k shares bringing the price down by a dime??
0 · Reply
rombrento
rombrento Apr. 21 at 8:02 PM
$DWTX
0 · Reply
DARKP00L
DARKP00L Apr. 20 at 11:52 AM
$DWTX $TC $JG
0 · Reply
DARKP00L
DARKP00L Apr. 20 at 10:18 AM
If you’re not in our community server, you’re missing out on 14 free days scanner access and algo! [Link in bio] $DWTX #stocks $TC #tradeideas $JG https://www.youtube.com/watch?v=DUIcM_RL6rU
0 · Reply
Drainomight
Drainomight Apr. 16 at 7:51 PM
$DWTX my guess is the trust is gone with this company. We’re gonna need something to hit the market before any movement happens.
0 · Reply
hammerfall43
hammerfall43 Apr. 16 at 2:17 PM
$DWTX r/s coming end 2026
0 · Reply
JAG_2_Trade
JAG_2_Trade Apr. 16 at 12:42 PM
$DWTX Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
0 · Reply
CHItraders
CHItraders Apr. 15 at 1:02 PM
$DWTX Dogwood Therapeutics Announces FDA Acceptance of SP16 Investigational New Drug Application for the Treatment of Chemotherapy Induced Pain and Neuropathy
0 · Reply
biotrade123
biotrade123 Apr. 15 at 10:31 AM
$DWTX PM vol 235k?? what news??
1 · Reply
Drainomight
Drainomight Apr. 9 at 6:46 PM
$DWTX let’s go dogwood
0 · Reply
Drugtrade
Drugtrade Apr. 7 at 1:54 PM
$DWTX $TCRX $ALGS nice market to play picks a few i like atm
0 · Reply